EMA Authorised: Velphoro (sucroferric oxyhydroxide) — Vifor Fresenius Medical Care Renal Pharma France

View source ↗

Summary

The EMA authorized Velphoro (sucroferric oxyhydroxide) for the treatment of hyperphosphatemia in patients with chronic kidney disease on renal dialysis; the mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• VELPHORO (sucroferric oxyhydroxide)

Snippet

Status: Authorised. Therapeutic area: Hyperphosphatemia;Renal Dialysis. MAH: Vifor Fresenius Medical Care Renal Pharma France. Decision date: 12/02/2026